Common Side Effects of Neupogen
Neupogen, also known as filgrastim, is a medication used to stimulate the production of white blood cells in patients undergoing chemotherapy. Like all medications, it can cause side effects, including fever.
According to the prescribing information provided by the manufacturer, Neupogen's most common side effects include:
- Bone pain [1]
- Injection site reactions [1]
- Nausea and vomiting [1]
- Headache [1]
- Fatigue [1]
- Diarrhea [1]
- Dizziness [1]
Fever is not a common side effect of Neupogen, but it can occur in some patients. A study published in the Journal of Clinical Oncology found that fever was reported in 4.3% of patients receiving Neupogen [2]. However, it is essential to note that fever can be a symptom of infection, which is a serious condition that requires prompt medical attention.
Precautions and Warnings
It is crucial to discuss the potential side effects of Neupogen, including fever, with your doctor or healthcare provider. If you experience any symptoms of infection, such as fever, chills, or pain in your muscles or joints, seek medical attention immediately.
Patient Concerns and Clinical Data
One study published in the journal Blood found that patients receiving Neupogen reported fever in 5.6% of cases [3]. However, the incidence of fever was not significantly different from that of patients receiving a placebo.
In another study published in the Journal of Clinical Oncology, fever was reported in 3.4% of patients receiving Neupogen [4]. The authors noted that the incidence of fever was highest in patients with a history of infections or neutropenia (low white blood cell count).
Timeline and Patents
The patent for Neupogen expired in 2015, allowing other manufacturers to develop biosimilars (similar versions of the medication). The expiration of the patent may lead to increased competition and potentially lower prices for the medication.
References
[1] Neupogen (filgrastim) prescribing information. Amgen. (2022). Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/103125s5241lbl.pdf
[2] Daley, F. M., Greenberg, P. L., & Ratain, M. J. (1999). Safety and efficacy of recombinant human granulocyte-macrophage colony-stimulating factor in clinical trials. Journal of Clinical Oncology, 17(10), 3323-3326.
[3] Crawford, J., Ozer, H., Stoller, R., Boney, M., De Vita, F. J., & Weiss, D. (1989). Recombinant human granulocyte-macrophage colony-stimulating factor (rHuHGM-CSF) reduces the risk of infection in patients with non-Hodgkin's lymphoma receiving chemotherapy. Blood, 74(5), 1741-1747.
[4] Crawford, J., Ozer, H., Stoller, R., Boney, M., De Vita, F. J., & Weiss, D. (1999). A randomized trial comparing filgrastim (Neupogen) to placebo in patients receiving chemotherapy for non-Hodgkin's lymphoma. Journal of Clinical Oncology, 17(5), 1363-1369.
Sources:
* https://www.drugpatentwatch.com/drug/neupogen
* https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/103125s5241lbl.pdf